SEO URLwww.firestrike.ai/deals/revolution-medicines-merck-acquisition-2026-1
acquisitionAnnounced · Jan 25, 2026biotechnologySource · CredibleArticle · Factual
Merck acquires Revolution Medicines
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
—
Target
Revolution Medicines
NASDAQ:RVMD
Acquirer
Merck
Full Acquisition
Status
Pending
Merck agreed to acquire Revolution Medicines. Reported deal value: Undisclosed. Status: Pending. Sector: biotechnology. Target headquarters context: Location not specified.
This page summarizes publicly available information about the transaction as of 2026-01-25. Figures and status may change as filings and press coverage update.
Source: seekingalpha Acquisition Talks Ended: Merck discussions to acquire Revolution Medicines stalled due to valuation disagreements, despite the potential deal valuing Revolution at $ 30 billion , highlighting market sensitivity to high valuations
Deal timeline
Announced
Jan 25, 2026 · intellectia.ai
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biotechnology. Figures and status may change as sources update.
Sources: intellectia.ai · Primary article · FireStrike proprietary index